Charles River Laboratories
644 hedge funds and large institutions have $13.5B invested in Charles River Laboratories in 2022 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 262 increasing their positions, 235 reducing their positions, and 115 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 262 | Existing positions reduced: 235
0.8% more ownership
Funds ownership: 93.47% → 94.28% (+0.8%)
1% less call options, than puts
Call options by funds: $77.7M | Put options by funds: $78.4M
9% less funds holding
Funds holding: 707 → 644 (-63)
24% less capital invested
Capital invested by funds: $17.7B → $13.5B (-$4.23B)
48% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 115
53% less funds holding in top 10
Funds holding in top 10: 15 → 7 (-8)
Top Buyers
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$142M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$118M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$111M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$86.9M |
| 5 |
ESCM
Echo Street Capital Management
New York
|
-$65.1M |
CRL Hedge Fund Activity: Q1 2022 in Review
644 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2022, worth a combined $13.5B — down 24% from $17.7B a quarter earlier.
Sellers outnumbered buyers: 115 funds closed out of CRL and 60 opened new positions — a net loss of 55 holders — while 235 trimmed existing stakes and 262 added.
The largest buyer was Mackenzie Financial, adding an estimated $171M. The largest seller was Invesco, cutting an estimated $142M.
- 644 institutional investors held Charles River Laboratories (CRL) as of Q1 2022, down from 707 in Q4 2021.
- Funds reported $13.5B of Charles River Laboratories stock for Q1 2022, down 24% quarter-over-quarter.
- 60 funds opened new Charles River Laboratories positions in Q1 2022 and 115 closed out, a net change of -55 holders.
- The largest Charles River Laboratories buyer in Q1 2022 was Mackenzie Financial, an estimated $171M added.
- The largest Charles River Laboratories seller in Q1 2022 was Invesco, an estimated $142M sold.
Based on aggregated 13F filings for Q1 2022.